FBRX Stock Catalyst: Forte Biosciences Reports Statistically Significant Improvement in Vitiligo with FB102

Jul 9, 2026 · 8:10am ET

Results observed at Week 24 after completion of 12-week treatment period.

Max move

+85.3%

High of day $38.96

Sparker timei

8:10am ET

FBRX · Jul 9, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Forte Biosciences, Inc. (Nasdaq: FBRX) announced on July 9, 2026, that its investigational drug FB102 demonstrated a statistically significant improvement in vitiligo symptoms at Week 24 following a 12-week treatment period. The results were compared to a placebo group.

The company disclosed the findings in an 8-K filing with the SEC. The treatment showed efficacy beyond the initial treatment phase, indicating sustained benefits for patients.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time FBRX sparks.

Download Sniper App →

Catch the next FBRX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →